MedTrace Logo

Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine

NCT03542227 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2022-11-08

No results posted yet for this study

Summary

The aim of the study is to develop and implement robust analytical protocols for first-void urine sample preparation and antibody assays to monitor vaccine induced immunity against HPV (Human Papillomavirus).

Conditions

  • Human Papilloma Virus Infection

Interventions

OTHER

First-void urine collection

Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.

OTHER

Blood draw

Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.

Sponsors & Collaborators

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Pierre Van Damme, Prof, MD, PhD · Universiteit Antwerpen

  • Ilse De Coster, MD · Universiteit Antwerpen

  • Wiebren A. A. Tjalma, Prof, MD, PhD · University Hospital, Antwerp

Eligibility

Min Age
16 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2022-01-11
Completion
2022-06-23

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542227 on ClinicalTrials.gov